Shots:
- The EC has approved Redemplo as an adjunct to diet to reduce triglycerides (TGs) in adults with Familial Chylomicronemia Syndrome (FCS), backed by the P-III (PALISADE) trial assessing it (25 & 50mg, SC, Q3M) vs PBO in 75 FCS adults
- Trial met its 1 & all multiplicity-controlled key 2EPs. 25mg showed an 80% vs 17% median TG reduction, while pooled plozasiran groups demonstrated 83% lowerodds of acute pancreatitis
- Redemplo is also being investigated in the P-III trial for adults with severe hypertriglyceridemia: SHASTA-3, SHASTA-4, & SHASTA-5, and P-III (MUIR-3) trial for adults with hypertriglyceridemia
Ref: Businesswire | Image: Arrowhead | Press Release
Related News: Arrowhead Pharmaceuticals Licenses ARO-PNPLA3 to Madrigal Pharmaceuticals in a ~$1B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
